Abstract
Liver is an important target for thyroid hormone actions. T3 exerts its effects by two mechanisms: (i) Genomic actions consisting of T3 link to nuclear receptors that bind responsive elements in the promoter of target genes, (ii) non‐genomic actions including integrin αvb3 receptor‐mediated MAPK/ERK and PI3K/Akt/mTOR‐C1 activation. SREBP‐1a, SREBP‐1c, and SREBP‐2 are transcription factors involved in the regulation of lipogenic genes. We show in Hep G2 cells that T3 determined a dose‐ and time‐dependent increase in the level of the precursor form of SREBP‐1 without affecting SREBP‐1 mRNA abundance. T3 also induced phosphorylation of ERK1/2, Akt and of mTOR‐C1 target S6K‐P70, and the cytosol‐to‐membrane translocation of PKC‐α. Modulation of SREBP‐1 protein level by T3 was dependent on MAPK/ERK, PI3K/Akt/mTOR‐C1 pathway activation since the MEK inhibitor PD98059 or the PI3K inhibitor LY294002 abolished the stimulatory effect of T3. Conversely, the effect of T3 on SREBP‐1 level was enhanced by using rapamycin, mTOR‐C1 inhibitor. These data suggest a negative control of mTOR‐C1 target S6K‐P70 on PI3K/Akt pathway. The effect of T3 on SREBP‐1 content increased also by using PKC inhibitors. These inhibitors increased the action of T3 on Akt phosphorylation suggesting that conventional PKCs may work as negative regulators of the T3‐dependent SREBP‐1 increase. T3 effects were partially abrogated by tetrac, an inhibitor of the T3‐αvβ3 receptor interaction and partially evoked by T3 analog T3–agarose. These findings support a model in which T3 activates intracellular signaling pathways which may be involved in the increment of SREBP‐1 level through an IRES‐mediated translation mechanism. J. Cell. Physiol. 227: 2388–2397, 2012.

This publication has 62 references indexed in Scilit: